ClinicalTrials.gg
RecruitingNCT06309511SEVR-HTUpdated Aug 3, 2025

Subendocardial Viability Ratio in Hypertension

An observational study in Hypertension, sponsored by Istituto Auxologico Italiano. Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertension by Istituto Auxologico Italiano — 5 open to participants now, 5 under way, none of them phase 3. Hypertension · Istituto Auxologico Italiano.

Started
2022
with 3 others
Observational
7 of 14
3 open now
Registered
13th of 14
by date

Among the 14 studies in Hypertension by Istituto Auxologico Italiano, this one is one of 4 that started in 2022, is one of 7 observational ones, and was the 13th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 14 studies in Hypertension by Istituto Auxologico Italiano are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertension by Istituto Auxologico Italiano, or all of them as a file.
02

Study summary

The aim of the research is to evaluate the Subendocardial Viability Ratio (SEVR) in hypertensive patients, using non-invasive arterial tonometry, and to establish the influencing factors and the possibility of predicting cardiovascular morbidity and mortality in arterial hypertension.

The SEVR will be evaluated on all patients belonging to the Arterial Hypertension Centers undergoing non-invasive arterial tonometry.

The SEVR is calculated on the morphology of the central pressure wave as the ratio between the DPTI (diastolic pressure-time index), i.e. the area between the carotid pressure curve and the ventricular pressure curve during the diastolic phase, and the SPTI ( systolic pressure-time index), i.e. the area under the carotid pressure curve during the systolic phase.

The SEVR will be correlated with the anthropometric and pathology variables which will be collected in an appropriate database.

03

Conditions studied

  • Hypertension

Keywords

  • Myocardial ischemia
  • Buckberg index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hypertensive patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hypertension

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testArterial tonometry

    Arterial transcutaneous tonometry

06

What researchers measure

Primary outcomes

  1. Buckberg index

    Assessment of subendocardial viability ratio (SEVR)

    Time frame: At recruitment, at 1 year, 2 years, 3 years and 4 years of follow-up

07

Study locations

5 of 5 sites recruiting
  • Centro di Prevenzione e Cura dell'Ipertensione Arteriosa "Alessandro Filippi"
    Mascalucia, Catania, Italy
    Recruiting
  • Unità Operativa Semplice Dipartimentale Ipertensione Arteriosa "Anna Maria Pirrelli", Università degli Studi di Bari "Aldo Moro". Policlinico Consorziale di Bari
    Bari, Italy
    Recruiting
  • Istituto Auxologico Italiano IRCCS
    Milan, 20145, Italy
    Recruiting
  • Medicina II Cardiovascolare, AUSL-IRCCS di Reggio Emilia
    Reggio Emilia, Italy
    Recruiting
  • Dipartimento di Scienze Mediche, Chirurgiche e della Salute, Università degli studi di Trieste
    Trieste, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 50 months is above that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Mar 13, 2024
StartActual
Oct 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06309511
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Oct 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 3, 2025

Study contacts

Paolo Salvi, MD
Contact
p.salvi@auxologico.it
+390261911 ext. 2968

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion